What can we learn from the edaravone development program for ALS?

References

• Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15:222–9.
   PubMed Web of Science ®Google Scholar
• The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
   PubMed Web of Science ®Google Scholar
• Mitusbishi Tanabe Pharma Corporation. Radicut® inj. and Radicut Bag for I.V. Infusion 30 mg. Mitsubishi Tanabe Corporation receives approval for additional indication for Amyotrophic Lateral Sclerosis (ALS) in Japan. Osaka, Japan; 2015.
   Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group [see comments]. N Engl J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425–31.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Tahara M, Todo S. The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther. 2008;26:101–14.
   PubMed Web of Science ®Google Scholar
• Higashi Y. Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress. Expert Opin Pharmacother. 2009;10:323–31.
   PubMed Web of Science ®Google Scholar
• Tanahashi N, Fukuuchi Y. Treatment of acute ischemic stroke: recent progress. Intern Med. 2002;41:337–44.
   PubMed Web of Science ®Google Scholar
• Wang CX, Shuaib A. Neuroprotective effects of free radical scavengers in stroke. Drugs Aging. 2007;24:537–46.
   PubMed Web of Science ®Google Scholar
• Kitagawa Y. Edaravone in acute ischemic stroke. Intern Med. 2006;45:225–6.
   PubMed Web of Science ®Google Scholar
• Takei K, Watanabe K, Yuki S, Akimoto M, Satakata T, Palumbo JM. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;([epub ahead of print]).
   Web of Science ®Google Scholar
• Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006;67:20–7.
   PubMed Web of Science ®Google Scholar
• Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis. 2007;26:1–13.
   PubMed Web of Science ®Google Scholar
• Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010;11:1753–63.
   PubMed Web of Science ®Google Scholar
• Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, Ito H, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213:448–55.
   PubMed Web of Science ®Google Scholar
• Aoki M, Warita H, Mizuno H, Suzuki N, Yuki S, Itoyama Y. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Res. 2011;1382:321–5.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Iwasaki Y. Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the wobbler mouse. PLoS One. 2015;10:e0140316.
   PubMed Web of Science ®Google Scholar
• Gladman M, Cudkowicz M, Zinman L. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis. Curr Opin Neurol. 2012;25:735–42.
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol. 1997;42:326–34.
   PubMed Web of Science ®Google Scholar
• Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol. 1997;42:644–54.
   PubMed Web of Science ®Google Scholar
• Abe K, Pan LH, Watanabe M, Kato T, Itoyama Y. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett. 1995;199:152–4.
   PubMed Web of Science ®Google Scholar
• Sasaki S, Shibata N, Komori T, Iwata M. iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis. Neurosci Lett. 2000;291:44–8.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1999;46:129–31.
   PubMed Web of Science ®Google Scholar
• Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;7:241–5.
   PubMed Web of Science ®Google Scholar
• Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–17.
   PubMed Web of Science ®Google Scholar
• The Writing Group on Behalf of the Edaravone (MCI-186) ALS17 Study Group. Exploratory Double-blind, Parallel-group, Placebo-controlled Extension Study of Edaravone (MCI-186) in Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017;([epub ahead of print]).
   Web of Science ®Google Scholar
• The Writing Group on Behalf of the Edaravone (MCI-186) ALS 18 Study Group. A Double-blind, Parallel-group, Placebo-controlled, 24-week, Exploratory Study of Edaravone (MCI-186) for the Treatment of Advanced Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017;([epub ahead of print]).
   Web of Science ®Google Scholar
• The Edaravone (MCI-186) ALS 16 Study Group. A Post-hoc Analysis of Outcomes in the First Phase 3 Clinical Study of Edaravone (MCI-186) in Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017;([epub ahead of print]).
   Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435–42.
   PubMed Web of Science ®Google Scholar
• Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, et al. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy. Neurol Neuroimmunol Neuroinflamm. 2015;2:e100.
   PubMed Web of Science ®Google Scholar
• Takei KL,S, Takahashi F, Tsuda K, Palumbo JM. Post-hoc analysis of randomized, placebo-controlled, double-blind study (MCI-186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;([epub ahead of print]).
   Web of Science ®Google Scholar
• Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:162–8.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059–67.
   PubMed Web of Science ®Google Scholar
• The Writing Group on Behalf of the Edaravone (MCI-186) ALS 19 Study Group. Open-label, 24-week Extension Study of Edaravone (MCI-186) in Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;([Epub ahead of print]).
   Web of Science ®Google Scholar
• Unno Y, Katayama M, Shimizu H. Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy. Clin Drug Investig. 2010;30:143–55.
   PubMed Web of Science ®Google Scholar
• Nakamaru Y, Kinoshita S, Kawaguch A, Takei K, Palumbo JM, Suzuki M. Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations. Amyotroph Lateral Scler Frontotemporal Degener. 2017;([epub ahead of print]).
   PubMed Web of Science ®Google Scholar
• Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323–30.
   PubMed Web of Science ®Google Scholar
• Bakker LA, Schroder CD, van Es MA, Westers P, Visser-Meily JMA, van den Berg LH. Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model. J Neurol. 2017;264:1413–20.
   PubMed Web of Science ®Google Scholar